Article

Recent successes of tissue bioengineering in ophthalmology highlighted

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Dr. Ellis-Behnke and his team at MIT conducted in vivo experiments in young and adult hamsters. After making a deep cut in the superior colliculus, the researchers injected a clear substance containing a self-assembling material made of peptides. This serves as a matrix for new cell growth. The researchers observed new axon growth first in young animals, then carried out a similar experiment in adults in a way that removed all visually-guided orienting behavior, Dr. Ellis-Behnke said.

Six weeks after the cut was made, the researchers began testing the animals and found complete regeneration and functional vision in all but two of the treated animals. In those two, the lack of improvement apparently was due to surgical error, Dr. Ellis-Behnke said. While the animals displayed some signs of healing, it was insufficient to drive their behavior.

In separate experiments, Dr. Ellis-Behnke and colleagues showed that axon growth could be seen in live animals.

Ultimately, they hope to apply these findings on self-assembling peptides and axon growth to humans, Dr. Ellis-Behnke concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.